Treatment Arms Were Balanced in the Phase 3 NOVA Study of ZEJULA1
Baseline Patient Characteristics Across Cohorts1
*One patient received one line of prior therapy.
BRCA, breast cancer susceptibility gene; ECOG, Eastern Cooperative Oncology Group; gBRCAmut, germline BRCA mutated; min, minimum; max, maximum; non-gBRCAmut, not germline BRCA mutated.
Reference: 1. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164.
See the clinical rigor behind the pivotal trial design for ZEJULA
View PFS in the gBRCAmut & non-gBRCAmut cohorts
Learn about the safety and tolerability of ZEJULA
See the pivotal phase 3 trial publication